Discovery of novel benzimidazole resistance mechanisms
发现新的苯并咪唑耐药机制
基本信息
- 批准号:10438771
- 负责人:
- 金额:$ 68.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAlbendazoleAllelesAnthelminticsBiological AssayCRISPR/Cas technologyCaenorhabditis elegansCollaborationsCommunitiesDrug DesignDrug TargetingEarly DiagnosisEconomic BurdenEnzymesEvolutionFarmFutureGenerationsGenesGeneticGenetic CrossesGenomeGenomicsGoalsGrowthHaemonchusHelminthsHookwormsHumanKnowledgeLaboratoriesLongevityMeasuresMedicineModelingMolecularMonitorMorbidity - disease rateNematodaOxidesParasite resistanceParasitesParasitic nematodePersonsPharmaceutical PreparationsPhenotypePhylogenetic AnalysisPoisoningPopulationProductionProteinsResearchResearch PersonnelResistanceResourcesRuminantsSamplingSoilStructural BiologistTestingTimeTissuesTransgenic AnimalsTranslatingVeterinary MedicineX Chromosomebasebenzimidazolebenzimidazole resistancebeta Tubulindisability-adjusted life yearsexperimental studyfitnessfitness testfollow-upgamma Tubulingene discoverygenetic approachgenome editinggenome-widehealth economicsmortalitynoveloffspringpathogenprogramsresistance alleleresistance generesistance mechanismsuccess
项目摘要
Project summary:
Parasitic nematodes impose a massive health and economic burden across much of the developing world,
infecting over one billion people worldwide. The morbidity and mortality inflicted by these devastating
pathogens is partly curtailed by mass drug administration (MDA) programs that depend on the continued
efficacy of a limited portfolio of anthelmintic drugs. Benzimidazole (BZ) compounds are a widely used class of
broad-spectrum anthelmintics that are an indispensable component of this limited chemotherapeutic arsenal.
The prospects of BZ resistance pose a serious threat to the future success of nematode control programs.
These prospects have been realized in the veterinary domain following intensive BZ use and are predicted to
materialize in human medicine with increased selection caused by expanded MDA. Early detection of
resistance-associated alleles in nematode parasite populations is essential to the goal of slowing anthelmintic
resistance and extending the lifespan of this critical drug class. Based on research in the free-living nematode
Caenorhabditis elegans from thirty years ago, parasitic nematode researchers focus on one BZ target, a
nematode-specific beta-tubulin. Despite this knowledge, it is still a complete mystery (1) whether any alleles
cause resistance (i.e. go beyond correlation), (2) the nematode tissues that are sensitive to BZ poisoning,
and (3) the drug-target interactions that cause resistance. In Haemonchus contortus, we have collected both
validated sensitive and resistance samples, and longitudinal samples where resistance has developed over
time. These samples are not available in any human parasitic nematode species. Using quantitative
resistance assays on these resources, we have shown that BZ resistance goes well beyond this single beta-
tubulin target. However, we do not know these independent resistance mechanisms in C. elegans or parasite
species. In Aim 1, we will test explicitly whether alleles correlated with resistance in parasites actually cause
resistance, test the fitness effects of these alleles, identify the tissues targeted by BZ, and characterize the
molecular mechanism for how beta-tubulin in affected by benzimidazoles. In Aim 2, we will discover beta-
tubulin independent mechanisms of resistance using the tractable C. elegans model nematode. In Aim 3, we
will expand our results to H. contortus where genomic and validated strain resources enable discoveries of
conserved resistance mechanisms. It is not possible in any parasitic nematode species to accomplish these
goals. New discoveries are possible only through this interplay between the model nematode C. elegans and
the tractable veterinary parasitic nematode H. contortus. Our results will have direct impacts on how
treatments are administered and resistance is monitored in human parasitic nematodes.
项目总结:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erik Christian Andersen其他文献
Erik Christian Andersen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Erik Christian Andersen', 18)}}的其他基金
Genetic and genomic tools for C. briggsae research
用于 C. briggsae 研究的遗传和基因组工具
- 批准号:
10371532 - 财政年份:2022
- 资助金额:
$ 68.21万 - 项目类别:
Genetic and genomic tools for C. briggsae research
用于 C. briggsae 研究的遗传和基因组工具
- 批准号:
10582658 - 财政年份:2022
- 资助金额:
$ 68.21万 - 项目类别:
Discovery of novel benzimidazole resistance mechanisms
发现新的苯并咪唑耐药机制
- 批准号:
10190824 - 财政年份:2020
- 资助金额:
$ 68.21万 - 项目类别:
Discovery of Novel Benzimidazole Resistance Mechanisms
新型苯并咪唑耐药机制的发现
- 批准号:
10895749 - 财政年份:2020
- 资助金额:
$ 68.21万 - 项目类别:
Discovery of novel benzimidazole resistance mechanisms
发现新的苯并咪唑耐药机制
- 批准号:
10029488 - 财政年份:2020
- 资助金额:
$ 68.21万 - 项目类别:
Discovery of conserved molecular mechanisms underlying population-wide variation in toxin responses
发现人群毒素反应差异的保守分子机制
- 批准号:
10579336 - 财政年份:2019
- 资助金额:
$ 68.21万 - 项目类别:
Discovery of conserved molecular mechanisms underlying population-wide variation in toxin responses
发现人群毒素反应差异的保守分子机制
- 批准号:
10328239 - 财政年份:2019
- 资助金额:
$ 68.21万 - 项目类别:
Discovery of conserved molecular mechanisms underlying population-wide variation in toxin responses
发现人群毒素反应差异的保守分子机制
- 批准号:
10088449 - 财政年份:2019
- 资助金额:
$ 68.21万 - 项目类别:
Large scale nutrigenetics and genomics in a tractable metazoan model
易处理的后生动物模型中的大规模营养遗传学和基因组学
- 批准号:
9761523 - 财政年份:2017
- 资助金额:
$ 68.21万 - 项目类别:
Large scale nutrigenetics and genomics in a tractable metazoan model
易处理的后生动物模型中的大规模营养遗传学和基因组学
- 批准号:
9423155 - 财政年份:2017
- 资助金额:
$ 68.21万 - 项目类别:
相似国自然基金
Albendazole增强肿瘤免疫抑制黑素瘤的作用与机制研究
- 批准号:82003286
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
School versus community-based albendazole deworming for control of soil transmitted helminths in school-age children in the Philippines – a cluster randomised controlled trial
学校与社区阿苯达唑驱虫对比控制菲律宾学龄儿童的土壤传播蠕虫——一项整群随机对照试验
- 批准号:
nhmrc : 1139561 - 财政年份:2018
- 资助金额:
$ 68.21万 - 项目类别:
Project Grants
School versus community-based albendazole deworming for control of soil transmitted helminths in school-age children in the Philippines – a cluster randomised controlled trial
学校与社区阿苯达唑驱虫对比控制菲律宾学龄儿童的土壤传播蠕虫——一项整群随机对照试验
- 批准号:
nhmrc : GNT1139561 - 财政年份:2018
- 资助金额:
$ 68.21万 - 项目类别:
Project Grants
Liver cystic echinococcosis: pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)
肝囊型包虫病:新型单步经皮治疗程序(囊内阿苯达唑亚砜注射液)的临床前评估
- 批准号:
9072551 - 财政年份:2016
- 资助金额:
$ 68.21万 - 项目类别:
Liver cystic echinococcosis: pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)
肝囊型包虫病:新型单步经皮治疗程序(囊内阿苯达唑亚砜注射液)的临床前评估
- 批准号:
9237195 - 财政年份:2016
- 资助金额:
$ 68.21万 - 项目类别:
Liver cystic echinococcosis: pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)
肝囊型包虫病:新型单步经皮治疗程序(囊内阿苯达唑亚砜注射液)的临床前评估
- 批准号:
9433603 - 财政年份:2016
- 资助金额:
$ 68.21万 - 项目类别:
Combined Albendazole Plus Praziquantel in Subarachnoid NCC, DCC Application
阿苯达唑联合吡喹酮在蛛网膜下腔 NCC、DCC 中的应用
- 批准号:
9323836 - 财政年份:2015
- 资助金额:
$ 68.21万 - 项目类别:
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application
联合阿苯达唑和吡喹酮治疗蛛网膜下腔 NCC、CCC、铅应用
- 批准号:
9751405 - 财政年份:2015
- 资助金额:
$ 68.21万 - 项目类别:
Combined Albendazole Plus Praziquantel in Subarachnoid NCC, DCC Application
阿苯达唑联合吡喹酮在蛛网膜下腔 NCC、DCC 中的应用
- 批准号:
9752680 - 财政年份:2015
- 资助金额:
$ 68.21万 - 项目类别:
Combined Albendazole Plus Praziquantel in Subarachnoid NCC, DCC Application
阿苯达唑联合吡喹酮在蛛网膜下腔 NCC、DCC 中的应用
- 批准号:
9134890 - 财政年份:2015
- 资助金额:
$ 68.21万 - 项目类别:
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application
联合阿苯达唑和吡喹酮治疗蛛网膜下腔 NCC、CCC、铅应用
- 批准号:
9134908 - 财政年份:2015
- 资助金额:
$ 68.21万 - 项目类别:














{{item.name}}会员




